Drug-induced hepatic injury in children: a case/non-case study of suspected adverse drug reactions in VigiBase

被引:54
|
作者
Ferrajolo, Carmen [1 ,3 ]
Capuano, Annalisa [3 ]
Verhamme, Katia M. C. [1 ]
Schuemie, Martijn [1 ]
Rossi, Francesco [3 ]
Stricker, Bruno H. [1 ,2 ]
Sturkenboom, Miriam C. J. M. [1 ,2 ]
机构
[1] Erasmus Univ, Med Ctr, Dept Med Informat, NL-3000 CA Rotterdam, Netherlands
[2] Erasmus Univ, Med Ctr, Dept Epidemiol, NL-3000 CA Rotterdam, Netherlands
[3] Univ Naples 2, Dept Expt Med, Pharmacol Sect, Naples, Italy
关键词
case; non-case study; children; hepatotoxicity; spontaneous reporting database; SAFETY;
D O I
10.1111/j.1365-2125.2010.03754.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
center dot Drug-induced hepatic injury is one of the most important reasons for drug withdrawal in adults. center dot Very little is known about drug-induced hepatic injury in children and adolescents. WHAT THIS STUDY ADDS center dot The rate of hepatic injury as suspected adverse drug reactions in the paediatric population is low. center dot Drugs associated with hepatotoxicity in children and adolescents were mostly known to be associated with hepatotoxicity in adults as well. AIM To identify which drugs are associated with reports of suspected hepatic injury in children and adolescents. METHODS Using a worldwide pharmacovigilance database, VigiBase, we conducted a case/non-case study on suspected adverse drug reactions (ADRs) occurring in the population < 18 years old. Cases were all the records with hepatic ADRs and non-cases were all the other ADR records. Records regarding topically administered drugs were excluded from both groups. The association between drug and suspected hepatic ADRs was calculated using the reporting odds ratio (ROR) as a measure of disproportionality while adjusting for gender, country, reporter and calendar year. Sub-analyses were performed within therapeutic class and by excluding vaccination-related reports to reduce confounding. RESULTS Overall, 6595 (1%) out of 624 673 ADR records in children and adolescents concerned hepatic injury. Most of the reported hepatic injuries concerned children 12-17 years of age. Drugs that were most frequently reported as suspected cause and were associated with hepatic injury comprised paracetamol, valproic acid, carbamazepine, methotrexate, minocycline, zidovudine, pemoline, ceftriaxone, bosentan, ciclosporin, atomoxetine, olanzapine, basiliximab, erythromycin and voriconazole. The association between hepatotoxicity and all these drugs, except for basiliximab, is already known. CONCLUSIONS Drug-induced hepatic injury is infrequently reported (only 1% of total) as a suspected ADR in children and adolescents. The drugs associated with reported hepatotoxicity (paracetamol, antiepileptic and anti-tuberculosis agents) are known to be hepatotoxic in adults as well, but age related changes in associations were observed. VigiBase is useful as a start to plan further drug safety studies in children.
引用
收藏
页码:721 / 728
页数:8
相关论文
共 50 条
  • [1] METAMIZOL-INDUCED AGRANULOCYTOSIS: A CASE/NON-CASE STUDY OF SUSPECTED ADVERSE DRUG REACTIONS IN VIGIBASE
    Treceno, C.
    Velasco, V.
    Jimenez Serrania, M., I
    Martin Arias, L. H.
    Ibanez, L.
    Molokhia, M.
    Carvajal, A.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2012, 111 : 36 - 36
  • [2] Hepatic adverse drug reactions: a case/non-case study in Italy
    Motola, Domenico
    Vargiu, Antonio
    Leone, Roberto
    Cocci, Alfredo
    Salvo, Francesco
    Ros, Barbara
    Meneghelli, Ilaria
    Venegoni, Mauro
    Cutroneo, Paola Maria
    Vaccheri, Alberto
    Velo, Gianpaolo
    Montanaro, Nicola
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 63 (01) : 73 - 79
  • [3] Hepatic adverse drug reactions: a case/non-case study in Italy
    Domenico Motola
    Antonio Vargiu
    Roberto Leone
    Alfredo Cocci
    Francesco Salvo
    Barbara Ros
    Ilaria Meneghelli
    Mauro Venegoni
    Paola Maria Cutroneo
    Alberto Vaccheri
    Gianpaolo Velo
    Nicola Montanaro
    European Journal of Clinical Pharmacology, 2007, 63 : 73 - 79
  • [4] Drug-Induced Taste and Smell Alterations: A Case/Non-Case Study on an Italian Database of Adverse Drug Reactions
    Tuccori, M.
    Lapl, F.
    Testi, A.
    Cutroneo, P.
    Leoni, O.
    Rivolta, A. L.
    Costantini, D.
    Opri, S.
    Motola, D.
    Venegoni, M.
    Sottosanti, L.
    Santuccio, C.
    Blandizzi, C.
    Mugelli, A.
    Del Tacca, M.
    DRUG SAFETY, 2009, 32 (10) : 895 - 896
  • [5] Drug-induced vitiligo: a case/non-case study in Vigibase(R), the WHO pharmacovigilance database
    Anthony, Norah
    Bourneau-martin, Delphine
    Ghamrawi, Sarah
    Lagarce, Laurence
    Babin, Marina
    Briet, Marie
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2020, 34 (06) : 736 - 742
  • [6] Drug-induced dementia:: a case/non-case study in the french pharmacovigilance database
    Favreliere, S.
    Brunet, G.
    Saulnier, P. J.
    Merlet, I.
    Alkhidir, F.
    Perault-Pochat, M. C.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2007, 21 : 68 - 68
  • [7] Drug-induced dementia:: A case/non-case study in the French pharmacovigilance database
    Favreliere, Sylvie
    Lafay-Chebassier, Claire
    Alkhidir, Fuad
    Merlet, Isabelle
    Pochat, Marie-Christine Perault
    THERAPIE, 2007, 62 (06): : 507 - 511
  • [8] Drug-induced hyperprolactinaemia: A case/non-case study in the French pharmacovigilance database
    Petit, A
    Piednoir, D
    Germain, ML
    Trenque, T
    THERAPIE, 2003, 58 (02): : 159 - 163
  • [9] Drug-induced hearing loss: a case/non-case study in the French pharmacovigilance database
    Favreliere, Sylvie
    Delaunay, Paul
    Lebreton, Jean-Pascal
    Rouby, Franck
    Atzenhoffer, Martine
    Lafay-Chebassier, Claire
    Perault-Pochat, Marie Christine
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2020, 34 (03) : 397 - 407
  • [10] Analysis of Individual Case Reports in the WHO Database of Suspected Drug-Induced Hepatic Injury in Children
    Ferrajolo, C.
    Capuano, A.
    Verhamme, K. M. C.
    Schuemie, M.
    Rossi, F.
    Stricker, B. H. Ch.
    Sturkenboom, M. C. J. M.
    DRUG SAFETY, 2009, 32 (10) : 946 - 947